NCT02768389View on ClinicalTrials.gov

Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 6, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
GlioblastomaBrain Tumor
Interventions
DRUG

Bevacizumab

Subjects receive Bevacizumab as standard of care

BEHAVIORAL

Modified Atkins Diet

The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (\< 20gm/day).

Trial Locations (4)

43214

OhioHealth Research and Innovation Institute, Columbus

44106

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive cancer Center, Cleveland

45220

University of Cincinnati, Cincinnati

Sponsors
All Listed Sponsors
collaborator

University of Cincinnati

OTHER

collaborator

OhioHealth Research Institute

UNKNOWN

lead

Case Comprehensive Cancer Center

OTHER

NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter